These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 8073927)

  • 21. Targeting factors involved in bone remodeling as treatment strategies in prostate cancer bone metastasis.
    Vessella RL; Corey E
    Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6285s-6290s. PubMed ID: 17062715
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bone metastases in prostate cancer: a targeted approach.
    Storey JA; Torti FM
    Curr Opin Oncol; 2007 May; 19(3):254-8. PubMed ID: 17414645
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Skeletal-related events in urological cancer patients with bone metastasis: a multicenter study in Japan.
    Yokomizo A; Koga H; Shinohara N; Miyahara T; Machida N; Tsukino H; Uozumi J; Nishiyama K; Satoh F; Sakai H; Naito S
    Int J Urol; 2010 Apr; 17(4):332-6. PubMed ID: 20202004
    [TBL] [Abstract][Full Text] [Related]  

  • 24. DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process.
    Mori K; Le Goff B; Charrier C; Battaglia S; Heymann D; Rédini F
    Bone; 2007 Apr; 40(4):981-90. PubMed ID: 17196895
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Disseminated, lethal prostate cancer during human immunodeficiency virus infection presenting with non-specific features. Open questions for urologists, oncologists, and infectious disease specialists.
    Manfredi R; Fulgaro C; Sabbatani S; Dentale N; Legnani G
    Cancer Detect Prev; 2006; 30(1):20-3. PubMed ID: 16455210
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Markers of bone turnover for the management of patients with bone metastases from prostate cancer.
    Garnero P; Buchs N; Zekri J; Rizzoli R; Coleman RE; Delmas PD
    Br J Cancer; 2000 Feb; 82(4):858-64. PubMed ID: 10732759
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The diagnosis of prostate cancer dissemination].
    Garín JA; Mas AG
    Arch Esp Urol; 2006 Dec; 59(10):1011-20. PubMed ID: 17283714
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outcome in prostate cancer: association with endothelial nitric oxide synthase Glu-Asp298 polymorphism at exon 7.
    Medeiros RM; Morais A; Vasconcelos A; Costa S; Pinto D; Oliveira J; Ferreira P; Lopes C
    Clin Cancer Res; 2002 Nov; 8(11):3433-7. PubMed ID: 12429631
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors.
    Brown JE; Cook RJ; Major P; Lipton A; Saad F; Smith M; Lee KA; Zheng M; Hei YJ; Coleman RE
    J Natl Cancer Inst; 2005 Jan; 97(1):59-69. PubMed ID: 15632381
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vivo models of prostate cancer metastasis to bone.
    Singh AS; Figg WD
    J Urol; 2005 Sep; 174(3):820-6. PubMed ID: 16093963
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bone-directed treatments for prostate cancer.
    Saad F
    Hematol Oncol Clin North Am; 2006 Aug; 20(4):947-63. PubMed ID: 16861125
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular insights into prostate cancer progression: the missing link of tumor microenvironment.
    Chung LW; Baseman A; Assikis V; Zhau HE
    J Urol; 2005 Jan; 173(1):10-20. PubMed ID: 15592017
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of an animal model for prostate cancer cell metastasis to adult human bone.
    Tsingotjidou AS; Zotalis G; Jackson KR; Sawyers C; Puzas JE; Hicks DG; Reiter R; Lieberman JR
    Anticancer Res; 2001; 21(2A):971-8. PubMed ID: 11396190
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Serum osteoprotegerin as a novel marker of bone metastasis in prostate cancer].
    Chen HX; Li HZ; Li HJ; Shi BB; Jin W; Cheng XQ
    Zhonghua Wai Ke Za Zhi; 2007 Mar; 45(6):412-4. PubMed ID: 17537330
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gene-modified bone marrow cell therapy for prostate cancer.
    Wang H; Thompson TC
    Gene Ther; 2008 May; 15(10):787-96. PubMed ID: 18385769
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bone health in men with prostate cancer: diagnostic and therapeutic considerations.
    Saad F; Perrotte P; Bénard F; McCormack M; Karakiewicz PI
    Can J Urol; 2005 Jun; 12 Suppl 2():9-15. PubMed ID: 16018826
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Skeletal morbidity in men with prostate cancer: quality-of-life considerations throughout the continuum of care.
    Saad F; Olsson C; Schulman CC
    Eur Urol; 2004 Dec; 46(6):731-39; discussion 739-40. PubMed ID: 15548440
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Heterogeneous expression of MAGE-A genes in occult disseminated tumor cells: a novel multimarker reverse transcription-polymerase chain reaction for diagnosis of micrometastatic disease.
    Kufer P; Zippelius A; Lutterbüse R; Mecklenburg I; Enzmann T; Montag A; Weckermann D; Passlick B; Prang N; Reichardt P; Dugas M; Köllermann MW; Pantel K; Riethmüller G
    Cancer Res; 2002 Jan; 62(1):251-61. PubMed ID: 11782385
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multidisciplinary management of bone complications in prostate cancer and optimizing outcomes of bisphosphonate therapy.
    Saad F; Sternberg CN
    Nat Clin Pract Urol; 2007 Feb; 4 Suppl 1():S3-13. PubMed ID: 17264863
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer.
    Small EJ; Smith MR; Seaman JJ; Petrone S; Kowalski MO
    J Clin Oncol; 2003 Dec; 21(23):4277-84. PubMed ID: 14581438
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.